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ABSTRACT 
Cystic fibrosis transmembrane 
conductance regulator (CFTR) is a multi-domain 
membrane protein that functions as a 
phosphorylation-regulated anion channel. The 
interface between its two cytosolic nucleotide 
binding domains (NBDs) and coupling helices 
(CHs) conferred by intracellular loops (ICLs) 
extending from the channel pore domains has been 
referred to as a transmission interface and is 
thought to be critical for the regulated channel 
activity of CFTR. Phosphorylation of the 
regulatory (R) domain of CFTR by protein kinase 
A (PKA) is required for its channel activity.  
However, it was unclear if phosphorylation 
modifies the transmission interface. Here, we 
studied purified full-length CFTR protein using 
spectroscopic techniques to determine the 
consequences of PKA-mediated phosphorylation. 
Synchrotron radiation circular dichroism 
spectroscopy confirmed that purified full-length 
wild-type CFTR is folded and structurally 
responsive to phosphorylation. Intrinsic 
tryptophan fluorescence studies of CFTR showed 
that phosphorylation reduced iodide-mediated 
quenching, consistent with an effect of 
phosphorylation in burying tryptophans at the 
transmission interface. Importantly, the rate of 
phosphorylation-dependent channel activation was 
compromised by the introduction of disease-
causing mutations in either of the two CHs 
predicted to interact with NBD1 at the interface. 
Together, these results suggest that 
phosphorylation modifies the interface between 
the catalytic and pore domains of CFTR and that 
this modification facilitates CFTR channel 
activation. 
 
 
 
Cystic fibrosis (CF) is caused by 
mutations of an ATP-Binding Cassette (ABC) 
anion channel, cystic fibrosis transmembrane 
conductance regulator (CFTR). CFTR has two 
nucleotide binding domains (NBDs), two 
membrane-spanning domains (MSDs) and a 
regulatory (R) domain (1). The interface between 
the NBDs and MSDs of CFTR is an alpha-helical 
region consisting of intracellular loops (ICLs) and 
coupling helices (CHs) (1). The interface has been 
referred to as the transmission interface between 
the pore and catalytic domains of CFTR (2).   
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Our understanding of the molecular basis 
for phosphorylation-dependent regulation of 
channel activation has evolved considerably and 
we have gained greater insight into its complexity. 
The phosphorylation-regulated R domain of CFTR 
is a flexible, disordered region that undergoes 
dynamic interactions with other CFTR domains 
(3,4). Phosphorylation of the R domain is thought 
to alter multiple interactions with other CFTR 
domains, with certain interactions becoming 
weaker (4) and other interactions acquiring higher 
affinities (5,6). The regulation of domain:domain 
interactions has been studied using isolated 
domains and in chemical cross-linking studies of a 
full-length cys-less CFTR protein, that has all of 
its native cysteine residues mutated to other 
residues, with strategically inserted cysteine pairs. 
For example, studies of isolated CFTR domains 
suggest that phosphorylation of the phospho-
regulated insertion within NBD1 (the regulatory 
insertion, RI) decreases its interaction with the 
core of NBD1 and this in turn acts allosterically to 
promote interaction between CH1 of ICL1 and 
NBD1 at the transmission interface (4,7).  
Cysteine cross-linking studies in the full-
length protein showed that phosphorylation 
enhanced NBD1:NBD2 dimerization (1,8). Studies 
of the consequences of strategic single site 
mutations at the dimer interface supported the 
importance of this phosphorylation-regulated 
interface in channel activation (9,10).  In contrast 
to the above predictions based on isolated 
domains, chemical cross-linking studies of the 
full-length CFTR failed to show modification of 
the interaction between the CHs and the NBDs by 
phosphorylation (1,8). These findings do not 
support the previous hypothesis that this 
transmission interface between the pore and 
catalytic domains is regulated by phosphorylation. 
On the other hand, the previous hypothesis was 
supported by a recent study that showed that an 
isolated peptide derived from ICL1 disrupted 
phosphorylation-dependent activation of full-
length CFTR (11). Hence, there is considerable 
uncertainty regarding the regulation of the 
transmission interface by phosphorylation, 
highlighting the need to develop new approaches 
for its study in the context of the full-length 
protein.  
The goal of this study was to employ 
biophysical approaches that would permit insight 
into dynamic conformational changes caused by 
PKA phosphorylation in the purified full-length 
wild-type (Wt-) CFTR protein. Further, the 
relative importance of the CHs in phosphorylation-
dependent channel activation was probed in 
comparative studies of disease-causing mutations 
in these regions.  
 
RESULTS  
Purified full-length Wt-CFTR is properly 
folded and its structure is modified by PKA 
phosphorylation - Full-length Wt-CFTR was 
purified following expression in Sf9 membranes as 
previously described (12). Briefly, CFTR was 
extracted using the detergent, fos-choline-14, and 
CFTR (bearing a polyhistidine tag) was partially 
purified by virtue of the affinity of this tag to the 
Ni-NTA resin (12). Fos-choline-14 was replaced 
with n-Dodecyl β-D-maltoside (DDM) and the 
protein:detergent complex was eluted from the 
affinity matrix (12). The purified protein was 
treated with 200 nM PKA and 5 mM Mg-ATP on 
the Ni-NTA column to enable extensive washing 
as described (12) and phosphorylation at multiple 
consensus sites was confirmed previously using 
selected reaction monitoring-mass spectrometry 
(13). Our methods were successful in purifying 
full-length Wt-CFTR as shown by the single, 
silver-stained protein band running at the expected 
molecular weight of approximately 140-150 kDa 
for the core-glycosylated form (band B) of CFTR 
expressed in Sf9 cells (Fig. 1A). In a subset of our 
experiments, we confirmed that the purified full-
length Wt-CFTR is functional as a 
phosphorylation and ATP-regulated anion channel 
upon reconstitution in proteoliposomes using our 
previously published iodide efflux protocols 
(12,14).  
Synchrotron radiation circular dichroism 
(SRCD) spectroscopy was used to examine Wt-
CFTR. The spectra ressembled that of a protein 
with a high helical content as expected with 
negative peaks at 209 and 222 nm, and a positive 
peak at 192 nm (Fig. 1B). Furthermore, 
comparison of the spectra of non-PKA 
phosphorylated Wt-CFTR and PKA 
phosphorylated Wt-CFTR indicated a subtle yet 
significant increase in the peak at 192 nm, which 
corresponds to an increase in helical structure 
content (Fig. 1B). Indeed, the ratio of the 
magnitudes of the 192 and 222 nm peaks increased 
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from 1.74 in the non-PKA phosphorylated state to 
1.86 after PKA phosphorylation, a clear indication 
that the shapes of the curves are different and that 
the observed differences do not simply arise from 
different magnitudes of the spectra (15). Previous 
nuclear magnetic resonance (NMR) and CD 
spectroscopy studies on the isolated NBD1 and the 
R region (residues 654-838) have found that 
phosphorylation decreased the helical content of 
those isolated domains (4,16). Thus, the increase 
in helical structure upon PKA phosphorylation 
observed by SRCD in the full-length Wt-CFTR is 
likely due to allosteric effects induced by 
phosphorylation of the RI and R region (1,17).  
Previous intrinsic tryptophan fluorescence 
studies of the Escherichia coli vitamin B12 ABC 
transporter, BtuCD, have shown that the interface 
between the CHs conferred by the MSD subunits 
(BtuC) and the NBD subunits (BtuD) was 
sensitive to urea-mediated unfolding (18,19). 
According to the CFTR homology model based on 
the structure of Sav1866 that was generated by 
Dalton and colleagues (17), the tryptophan 
residues (tryptophans) endogenous to CFTR reside 
at the membrane:solvent interface and at the 
transmission (ICL:NBD) interface (Fig. 2, A and 
B). Thus, we were prompted to determine whether 
measurements of intrinsic tryptophan fluorescence 
of purified full-length Wt-CFTR could reveal 
phosphorylation-associated changes in urea-
mediated unfolding. DDM solubilized full-length 
Wt-CFTR exhibited a decrease in fluorescence 
intensity (Fig 3A inset) and a red shift in emission 
wavelength maxima (max) with increasing 
concentrations of urea, from its initial wavelength 
of 322 nm to its final wavelength of 332 nm (Fig. 
3, A and B). The decrease in fluorescence intensity 
and red shift in the max reported the change in the 
chemical environment of the tryptophans upon 
urea-induced unfolding of the protein. 
Interestingly, this red shift did not reach the max of 
355 nm observed in a N-Acetyl-L-
tryptophanamide (NATA) sample of free soluble 
tryptophan analogues (Fig. 3A), suggesting that 
urea failed to completely unfold CFTR. Hence, 
akin to the previous SRCD experiments, intrinsic 
tryptophan fluorescence studies also demonstrated 
that the purified protein is properly folded in DDM 
micelles.  
PKA phosphorylation shifted the 
concentration dependence for urea-induced 
unfolding to the right, from a midpoint urea 
concentration (Cm) of approximately 2.8 M in the 
non-PKA phosphorylated sample to a Cm of 
approximately 4.0 M in the PKA phosphorylated 
sample (Fig. 3B). In addition, the slope of the 
transition known as the “m” value was lower in 
the PKA phosphorylated condition: the “m” value 
was 0.8 kcal/molM-1 in non-PKA phosphorylated 
Wt-CFTR compared to 0.6 kcal/molM-1 in PKA 
phosphorylated Wt-CFTR (Fig. 3B). These 
findings suggest that PKA phosphorylation 
protected the chemical environment of 
endogenous tryptophans from urea-induced 
unfolding at either the membrane:solvent interface 
or at the ICL:NBD interface (Fig. 2, A and B).  
In order to determine whether the intrinsic 
tryptophan fluorescence measurements reported 
the effect of PKA phosphorylation on the 
membrane:solvent interface or on the ICL:NBD 
interface, fluorescence quenching studies were 
conducted to probe the environment of the 
tryptophans that were responsible for the intrinsic 
tryptophan fluorescence of purified full-length Wt-
CFTR. Quenchers of different polarity and charge 
were tested which include: polar and uncharged 
acrylamide, negatively charged iodide, and 
positively charged cesium salt. As expected, 
NATA was readily quenched by all quenchers 
with high Stern-Volmer constant (Ksv) values 
(Table 1) as the tryptophan analogues were 
completely exposed to the solvent and were 
therefore highly accessible to the quenchers. In 
contrast, tryptophans intrinsic to full-length Wt-
CFTR were relatively resistant to quenching with 
significantly lower Ksv values compared to NATA 
as expected for a properly folded protein (Table 
1). Interestingly, all quenchers reduced the 
intrinsic tryptophan fluorescence of purified full-
length Wt-CFTR in a linear fashion suggesting 
that only one cluster of tryptophans was reported 
for each quencher of this assay (Fig. 3, C – E).  
Quenching with polar and uncharged 
acrylamide was not affected by the 
phosphorylation status of CFTR (Fig. 3C). We 
propose that acrylamide quenching may be 
reporting the membrane:solvent interface due to its 
difficulty to diffuse across the membrane (20). In 
contrast, quenching with charged quenchers, 
iodide and cesium, were dependent on its 
phosphorylation status (Fig. 3, D and E). PKA 
phosphorylation of purified CFTR led to a lower 
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Ksv value upon quenching with negatively charged 
iodide whereas it led to a higher Ksv value upon 
quenching with positively charged cesium (Table 
1). Based on their properties, the charged 
quenchers may be reporting the cluster of 
tryptophans at the cytosol. In addition, the 
negative charge conferred by phosphorylation may 
have modulated the propensity of the reporting 
tryptophans to be quenched by aqueous, charged 
agents. Interestingly, there is a phosphorylation 
site, pSer422 on the RI [which Lewis and 
colleagues report it as residues 413-428 (21) 
whereas Aleksandrov and colleagues report it as 
residues 404-435 (22)] of NBD1, which is 
proximal to the ICL:NBD1 interface (4,7,23,24). 
Previous NMR studies have suggested that 
phosphorylation at pSer422 enhanced interactions 
at the ICL1:NBD1 and ICL4:NBD1 interfaces 
(4,7,23). Based on these results, we propose that 
PKA phosphorylation may be modifying the 
electrostatic environment of the ICL:NBD1 
interface as there are multiple tryptophans 
(including residues 401, 496 and 1063) residing in 
proximity to the putative transmission interface 
consisting of CH1, CH4 and NBD1 which may be 
reported in the intrinsic tryptophan fluorescence 
studies (Fig. 2B).  
Cysteine cross-linking studies using a 
membrane permeable sulphydryl modifying 
reagent confirmed a physical interaction between 
CH4 of ICL4 and NBD1 - Previous studies 
investigating phosphorylation-dependent changes 
in the affinity of the CHs and NBD1 used 
chemical cross-linking of cysteine pairs introduced 
on opposing surfaces of NBD1 and CH1 or CH4 
(Fig. 4A); cysteine pairs were introduced at 
positions previously shown to reside at these 
domain:domain interfaces in a CFTR construct 
lacking native cysteines (cys-less CFTR) (1,8). 
These cross-linkers were long and membrane 
impermeable, necessitating the application of these 
sulphydryl reagents to inside-out membrane 
vesicles (1,8). In the current work, we were 
prompted to determine if phosphorylation-
dependent changes in cysteine cross-linking could 
be detected using the short (8 angstroms) and 
membrane permeable maleimide reagent, 
bismaleimidoethane (BMOE), as this was 
previously successful in capturing 
phosphorylation-dependent changes of the 
NBD1:NBD2 interface in full-length cys-less 
CFTR (10).  
Firstly, we confirmed that the cysteine 
mutants were expressed at the cell surface in 
human embryonic kidney (HEK)-293 GripTite 
cells as shown by the presence of complex-
glycosylated form of the protein (band C) in the 
immunoblot (Fig. 4A). In addition, CFTR 
activation of the cysteine mutants was studied 
using the membrane potential plate reader assay: 
FLIPR (25). As shown in Figure 4B, all of the 
cysteine mutants were functionally expressed as 
cAMP-activated conductances. Interestingly, the 
overall rate of activation was significantly reduced 
in V510C/A1067C cys-less CFTR (Fig. 4C). This 
defect could reflect a disulphide bond formation 
for the pair of cysteines introduced at CH4 and 
NBD1 which could account for attenuation of 
channel activity by modifying important dynamic 
conformational changes as previously suggested 
(1,8).  
As in previous studies by Mense and 
colleagues, we studied cross-linking of cysteine 
pairs in cys-less CFTR using a cell permeable 
maleimide cross-linker, BMOE (10). Previous 
studies have shown that V510C on NBD1 and 
A1067C on CH4 were in close proximity and 
could be cross-linked with a methane-
thiosulfonate reagent in membrane vesicles (8,26). 
Thus, we studied those substitutions to confirm the 
efficacy of BMOE in capturing such interactions 
in intact cells. A unique molecular weight band 
(band X) above 250 kDa only appeared with 
BMOE treatment of cells expressing cys-less 
CFTR bearing two cysteines in the same protein 
(V510C/A1067C) (Fig. 5B) and not in cells 
expressing cys-less CFTR with single cysteines 
(V510C or A1067C) or co-expressing single 
cysteines from different cys-less CFTR constructs 
(V510C+A1067C) (Fig. 5A). This finding 
confirmed that the membrane permeable cross-
linker, BMOE, can effectively cross-link 
interacting residues within CFTR.  
Previous studies have suggested that R170 
of CH1 interacts with residues of NBD1 (i.e. 402, 
403 or 407) (1,27). From our intrinsic tryptophan 
fluorescence studies, W401 was a residue of 
interest that may be in close proximity to the 
transmission interface (Fig. 2B). Thus, the 
R170C/W401C mutant was generated to study the 
predicted interaction of those residues at the 
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ICL1:NBD1 interface. Band X was not detected 
upon BMOE addition to cells expressing 
R170C/W401C, single cysteine mutants (R170C 
or W401C) or co-expressing single cysteines from 
different cys-less CFTR constructs 
(R170C+W401C) (Fig. 5, A and B). We have also 
applied these studies on a different site of NBD1 
(by engineering a cysteine at E476), which was 
also predicted to interact with R170 of CH1 (27), 
to further interrogate the ICL1:NBD1 interface. 
Addition of BMOE to cells expressing 
R170C/E476C also failed to confer the appearance 
of the unique cross-linked band in SDS analyses 
(Fig. 5B). We did detect a modest increase in the 
apparent mass of band B of R170C/W401C and 
R170C/E476C cys-less CFTR after treatment with 
BMOE (Fig. 5B). However, we also observed a 
similar shift in CFTR protein bearing only one 
cysteine, such as R170C (Fig. 5A). We suggest 
that this change in mass does not represent cross-
linking, rather a change in conformation induced 
by BMOE modification of a single cysteine. 
Hence, the membrane permeable sulphydryl 
reagent, BMOE, was successful in capturing 
CH4:NBD1 but not CH1:NBD1 interactions in 
this study.  
 We then applied cysteine cross-linking 
studies to test our hypothesis that PKA 
phosphorylation modifies the ICL:NBD1 
interfaces. We could only test the effect of 
phosphorylation on the ICL4:NBD1 interface as 
we could not detect cysteine cross-linking at the 
ICL1:NBD1 interface as previously shown (Fig. 
5B). Phosphorylation has been shown to 
significantly enhance both band B and band C of 
Wt-CFTR over time (28). To address this effect, 
we acutely treated the V510C/A1067C protein 
with cAMP agonists, forskolin (Fsk) and 3-
isobutyl-1-methylxanthine (IBMX), for 30 
minutes and conducted cysteine cross-linking on 
ice. We did not detect a change in the relative 
abundance of band X between V510C and 
A1067C after PKA-mediated phosphorylation 
(Fig. 5, C and D). In separate experiments, we also 
showed that band X did not appear in studies of 
R170C/(W410C or E476C) after phosphorylation 
with the cAMP agonists (data not shown). 
Together, these chemical cross-linking results 
were consistent with previous studies that suggest 
that chemical cross-linking may not be a 
sufficiently sensitive approach to detect subtle 
interactions mediated by PKA phosphorylation at 
the ICL:NBD1 interfaces (1,8). Alternatively, it 
may be necessary to introduce cysteines at 
different positions in the cys-less CFTR protein in 
order to monitor phosphorylation-dependent 
changes in domain:domain affinity. For example, 
Corradi and colleagues predicted that the 
interaction between the X-loop of NBD1 and CH4 
may change with phosphorylation and initiation of 
the gating cycle of CFTR (2).    
Disease-causing mutations in the CHs of 
ICL1 and ICL4 attenuate the rate of CFTR 
channel activation - Multiple disease-causing 
mutations have been identified in the CHs of ICL1 
and ICL4, including R170G and A1067T, 
respectively (29). Both R170G and A1067T were 
predicted to reduce the helical propensity of ICL1 
and ICL4 with secondary structure prediction 
software (data not shown) and were shown to 
impair the biosynthetic maturation of the CFTR 
protein (Figure 6A, inset). These findings support 
the hypothesis that both CHs are important for 
CFTR assembly.   
In order to determine if these helix-
disrupting mutations also impair phosphorylation-
regulated channel activity, we compared their 
forskolin sensitivity and kinetics of channel 
activation relative to the Wt-CFTR protein.  Given 
the lower steady-state levels of mature CFTR 
protein exhibited by R170G and A1067T (Fig. 6A 
inset), it was not surprising to find that the peak of 
forskolin-mediated channel activity measured 
using the FLIPR assay was reduced for both 
mutant proteins relative to Wt-CFTR (Fig. 6A). 
However, the dose response for forskolin-
dependent activation was similar for the two 
mutants and Wt-CFTR protein (Fig. 6B). This 
result suggests that these mutants do not exhibit a 
defect in forskolin-mediated phosphorylation per 
se. On the other hand, the rates of activation with 
forskolin (added at 0.6 μM, the forskolin 
concentration closest to the half maximal effective 
concentration, EC50, of all the constructs) were 
significantly attenuated relative to the Wt-CFTR 
protein for both CH mutants (Fig. 6C). We 
interpret these findings to suggest that both CHs 
are required for phosphorylation-dependent 
activation of the channel gate.  
We used a structure prediction method 
called I-TASSER (30-33) to test our prediction 
that both of the mutations in CH1 and CH4 are 
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disruptive to the transmission interface comprising 
NBD1. I-TASSER modeled the full-length CFTR 
sequence by generating and clustering structural 
simulations with the SPICKER program and then 
aligning the transmembrane region to similar PDB 
structures of ABC transporters which include P-
glycoprotein, TM-0287, Atm1, PCAT1 and MsbA 
(30-33). We generated separate models of the full-
length protein bearing R170G, A1067T or both 
mutations (R170G+A1067T) for comparison. In 
Figure 6D, we show the change in the normalized 
temperature factor (B-factor), an indication of 
protein flexibility, at all of the residues of the full-
length mutant CFTR proteins relative to the Wt 
protein (excluding the R region as it is extremely 
flexible and can mask the effect of other structured 
regions of CFTR). The B-factor values were 
generated by an algorithm in I-TASSER known as 
ResQ which takes into account the changes in 
local structural assembly along with the sequence 
and structural profiles and then these values were 
normalized based on the z-scores (34). 
Interestingly, the models for all of the three mutant 
proteins exhibited the largest change in B-factor in 
regions other than the CHs. Rather, the largest 
change for both mutants was detected at the 
amino-terminal region of the RI (residues 405-
407) of NBD1 (Fig. 6D). These models suggest 
that both of these disease-causing mutations in 
CH1 or CH4 act allosterically to induce similar 
defects in the conformational stability of NBD1.  
Together with channel activity studies, this 
modeling supports the role of the transmission 
interface in mediating phosphorylation-dependent 
activation.    
 
DISCUSSION 
 The molecular mechanisms underlying the 
activation of CFTR channel function by PKA-
dependent phosphorylation, ATP binding and 
hydrolysis remain poorly understood, mainly due 
to the paucity of structural information regarding 
the full-length protein. Hypothetical models for 
CFTR channel activation have been developed on 
the basis of patch clamp studies (35-37), cross-
linking studies of cysteine-substituted CFTR in 
cellular membranes (8,10,38) and biophysical 
studies of isolated domains (4,7). In this work, the 
first spectroscopic studies of purified full-length 
CFTR together with cell-based studies of disease-
causing mutants support the importance of inter-
domain interactions between the MSDs and NBDs 
in phosphorylation-dependent channel activation. 
These findings provide a molecular framework 
which is important for advancing our 
understanding of regulated CFTR channel gating, 
the defects caused by CF-causing mutations and 
potentially the mechanism-of-action of small 
molecule modulators of CFTR channel function. 
 Although the interaction between the 
MSDs and NBDs of other ABC proteins (i.e. 
solute transporters) is thought to form a structural 
conduit important for regulating transport function 
(39-41), previous chemical cross-linking studies 
failed to detect a change in the proximity of these 
domains in CFTR, a unique ABC channel protein, 
after phosphorylation, a necessary trigger for 
channel activity (1,8). The present studies 
monitoring intrinsic tryptophan fluorescence in the 
purified full-length CFTR protein are the first to 
provide evidence supporting a model wherein 
phosphorylation modifies the affinity for coupling 
between the MSDs and NBDs of CFTR. Intrinsic 
tryptophan fluorescence studies showed that the 
propensity for urea-induced unfolding and 
fluorescence quenching by potassium iodide was 
reduced in the purified and highly phosphorylated 
CFTR protein relative to the basally 
phosphorylated protein. The water-accessible 
junction between the ICLs extending from the 
MSDs and the NBDs harbours multiple 
tryptophans and constitutes the region most likely 
to be modified by phosphorylation, although this 
needs to be confirmed in mutagenesis studies.  The 
inability to detect changes in steady-state chemical 
cross-linking in our current work and previous 
studies (1,8) support the claim that the CHs are 
always in close physical proximity to the NBDs in 
both the basally and highly phosphorylated CFTR 
protein. Together, our findings suggest that the 
affinity of this interaction is increased with 
phosphorylation. 
 The importance of the transmission 
interface involving NBD1 (conferred by both CH1 
and CH4) was substantiated in cell-based studies 
showing altered phosphorylation-dependent 
channel activation for two disease-causing 
mutations localized in these helices. Interestingly, 
rather than altering the sensitivity for the agonist 
of phosphorylation (forskolin), these mutations 
attenuated the kinetics of phosphorylation-
dependent activation which implicates a defect in 
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a secondary conformational change necessary of 
channel opening. Together, these data support a 
model wherein the interaction between the MSDs 
and NBDs of CFTR are modified by 
phosphorylation, and disruption of this 
transmission interface alters the kinetics of long-
range conformational changes vital for channel 
opening.   
 These studies are relevant to our 
understanding of the impact of the major mutant, 
deletion of phenylalanine at position 508 
(F508del), on CFTR channel function. This 
mutation, located in NBD1 at the interface where 
CH4 binds, is known to disrupt CFTR assembly, 
biosynthetic processing, and phosphorylation-
dependent channel gating (27,42,43). Relevant to 
the current work, it was previously reported that 
the rate of phosphorylation-dependent channel 
activation is attenuated in F508del-CFTR (44,45), 
a similar phenotype that we have described for the 
disease-causing mutations in CH1 (R170G) and 
CH4 (A1067T). Given our finding that both 
interfaces (constituted by CH1 and CH4) 
contribute to normal channel activation by 
phosphorylation, we hypothesize that small 
molecule stabilizers of the ICL1:NBD1 interface 
may augment the efficacy of modulators that 
partially rescue the defect in the ICL4:NBD1 
interface caused by F508del (i.e. Class I 
correctors). This concept was tested in part by 
Ehrhardt and colleagues (11) as they developed 
activators and inhibitors of CFTR channel activity 
by screening for enhancers or disruptors of the 
interaction of NBD1 with peptides derived from 
ICL1. In future studies, we would include the CH 
region of the ICL1 peptides that was absent in the 
peptides tested by Ehrhardt and colleagues (11) as 
our study shows that this region will be 
particularly effective in identifying modulators of 
phosphorylation-dependent activation in Wt-
CFTR and potentially F508del-CFTR. 
 Finally, the biophysical methods described 
in this work will also be useful in future studies 
aimed at elucidating the mechanisms underlying 
the activity of small molecule modulators, 
especially potentiators that enhance CFTR channel 
activity. We have previously shown that the 
potentiator, ivacaftor (VX-770), acts directly on 
the phosphorylated CFTR channel protein to 
enhance its ATP- dependent and independent 
channel openings (12). It will be interesting to 
determine if VX-770 binding enhances 
phosphorylation-dependent modification of the 
transmission interface by monitoring changes in 
intrinsic tryptophan fluorescence.  
 
EXPERIMENTAL PROCEDURES 
Purification of full-length Wt-CFTR – 
Full-length Wt-CFTR with a C-terminal 
polyhistidine (His10) tag was overexpressed in Sf9 
cells and crude membranes were prepared as 
previously described (12). Crude membranes were 
solubilized by 2% fos-choline-14 (Anatrace, 
Maumee, OH). CFTR was purified via affinity to 
Ni-NTA column and exchanged to n-Dodecyl β-
D-maltoside (DDM, BioShop Canada Ltd., 
Burlington, Ontario, Canada) detergent micelles. 
The purified protein sample was run on a 4-12% 
SDS-acrylamide gel and developed by the silver 
stain method. 
Synchrotron radiation circular dichroism 
spectroscopy - Full-length CFTR protein was 
purified in buffer (20 mM sodium phosphate, 25 
mM sodium chloride, 1 mM DDM, pH 7.2). The 
protein sample was split into two conditions: non-
PKA phosphorylated and PKA phosphorylated 
CFTR. In the PKA phosphorylated condition, 
purified CFTR was phosphorylated with 200 nM 
protein kinase A (PKA; New England Biolabs 
Ltd., Ipswich, MA) and 5 mM Mg-ATP (Sigma, 
St. Louis, MO) in buffer (20 mM sodium 
phosphate, 25 mM sodium chloride, 1 mM DDM, 
pH 7.2) on the Ni-NTA column (Qiagen, Hilden, 
Germany) as previously described (12). PKA (38 
kDa) was effectively washed out of the PKA 
phosphorylated sample with buffer (20 mM 
sodium phosphate, 25 mM sodium chloride, 1 mM 
DDM, pH 7.2 buffer) and a centrifugal filter with 
a cutoff of 100 kDa (Merck Millipore Ltd., 
Tullagreen, Ireland) as previously described (12). 
The non-PKA phosphorylated sample was also 
washed the same way as the PKA phosphorylated 
CFTR sample. SRCD spectra were obtained at the 
ISA synchrotron (Aarhus, Denmark) using a 0.1 
mm pathlength sealed Suprasil (Hellma Analytics, 
Müllheim, Germany) quartz cuvette. For each 
spectrum, a stepsize of 1 nm and an averaging 
time of 2 s were used. In each case, three replicate 
scans of the sample were subtracted from three 
scans of the baseline (20 mM sodium phosphate, 
25 mM sodium chloride, 1 mM DDM, pH 7.2 
buffer) and the net spectrum calibrated to a 
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spectrum of camphorsulfonic acid (CSA, Sigma) 
measured prior to data collection (46). Two 
sample loadings, each with three replicate scans, 
were conducted for each condition (non-PKA and 
PKA phosphorylated). Delta epsilon () curves 
were scaled as previously described (47). All 
processing was carried out using the CDTool 
software (48). Differences were identified from 
error bars (indicating reproducibility levels) at all 
wavelengths, set at 1 s.d.  
Intrinsic tryptophan fluorescence - 
Purified full-length Wt-CFTR was concentrated to 
concentrations between 50 and 70 g/ml as 
determined by the NanoDrop 2000 (1 Abs  1 
mg/ml, ThermoFisher) in buffer (25 mM HEPES, 
25 mM sodium chloride, 1 mM DDM, pH 7.2). 
Protein sample was split into two conditions: non-
PKA phosphorylated and PKA phosphorylated as 
previously described. Intrinsic tryptophan 
fluorescence studies of the purified protein were 
conducted on the Photon Technology International 
QM80 spectrofluorimeter (HORIBA Scientific, 
Edison, NJ) with bandwidths of 2 nm for both 
excitation and emission and using a 10 x 2 mm 
quartz cuvette (Hellma Analytics). Fluorescence 
traces were corrected for dilution, inner filter 
effect, scattering and background (via subtraction 
of the buffer fluorescence trace). 
Urea denaturation studies - Samples of 
130 l were then incubated at each urea 
concentration for 10 min at room temperature. 
Tryptophan residues were excited at 290 nm and 
emission scans were run from 300 to 400 nm. The 
maximum emission wavelength (max) at each urea 
concentration was determined and plotted against 
the urea concentration with GraphPad Prism 
(version 6.0c). Sigmoidal curves of emission 
wavelength maxima (λmax) were fitted to the 
following equation using GraphPad Prism: 
  
f(C) = (exp(-m*(Cm-C)/RT)/(1+exp(-m*(Cm-
C)/RT)))  
 
where “m” is the “m” value or slope of the urea 
denaturation curve, C is the individual urea 
concentration and Cm is the midpoint urea 
concentration (49). 3 M of N-acetyl-L-
tryptophanamide (NATA, Sigma) was used as a 
control in which all the tryptophan residues were 
exposed to the solvent environment. 
Quenching studies – Purified CFTR 
samples were titrated with 2 l titrations of 2.5 M 
stock concentrations of acrylamide, potassium 
iodide or cesium chloride quenchers dissolved in 
buffer (25 mM HEPES, 25 mM sodium chloride, 1 
mM DDM, pH 7.2). Fluorescence intensity at each 
quencher concentration was taken over a 20 s 
interval by excitation at 290 nm and emission at 
322 nm. Fluorescence intensities were averaged 
over the 20 s interval and corrected for 
background. Values of initial fluorescence 
intensity of purified CFTR without quenchers (F0) 
over fluorescence intensity at each quencher 
concentration (F) were plotted at each quencher 
concentration ([Q]). This plot known as a Stern-
Volmer plot generates a linear regression using 
GraphPad Prism with the following equation:   
 
F0/F = 1 + Ksv[Q] 
 
The Stern-Volmer constant (Ksv) was determined 
as the slope of each linear regression.   
Generation and expression of mutants – 
The full-length Wt-CFTR construct with all native 
cysteine residues mutated to other residues (cys-
less Wt-CFTR), the cys-less Wt-CFTR with 
V510C at NBD1 and A1067C at CH4 on separate 
plasmids and on the same plasmid 
(V510C/A1067C) were kindly provided by Dr. 
David Clarke (Toronto, Ontario, Canada) (26). To 
probe the ICL1:NBD1 interface, primers of 
R170C (Forward: 5'-CTT TAA AGC TGT CAA 
GCT GTG TTC TAG ATA AAA TAA G-3' and 
reverse: 5'-CTT ATT TTA TCT AGA ACA CAG 
CTT GAC AGC TTT AAA G-3'), W401C 
(Forward: 5'-GTA ACA GCC TTC TGT GAG 
GAG GGA TTT GG-3' and reverse: 5'-CCA AAT 
CCC TCC TCA CAG AAG GCT GTT AC-3') and 
E476C (Forward: 5'-GAT TAT GGG AGA ACT 
GTG TCC TTC AGA GGG TAA AAT TAA G-3' 
and reverse: 5'-CTT AAT TTT ACC CTC TGA 
AGG ACA CAG TTC TCC CAT AAT C-3') were 
designed to generate single and double cysteine 
mutants on the cys-less Wt-CFTR cDNA template 
that was kindly provided by Dr. David Clarke 
(26). Primers of disease-causing loop mutants, 
R170G (Forward: 5'-GAC TTT AAA GCT GTC 
AAG CGG TGT TCT AGA TAA AAT AAG-3' 
and reverse: 5'-CTT ATT TTA TCT AGA ACA 
CCG CTT GAC AGC TTT AAA GTC-3') and 
A1067T (Forward: 5’-GGA CAC TTC GTA CCT 
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TCG GAC GG-3’ and reverse: 5'-CCG TCC GAA 
GGT ACG AAG TGT CC-3'), were generated on 
full-length human Wt-CFTR cDNA (pcDNA3.1). 
Mutations were generated using the KAPA HiFi 
HotStart PCR Kit (KAPA Biosystems, Woburn, 
MA) and plasmid DNA was generated with the 
QIAprep Spin Miniprep Kit (Qiagen). Mutations 
were confirmed with DNA sequencing (TCAG, 
Toronto, Ontario, Canada). Plasmid DNA of 
mutants were transfected using Polyfect 
Transfection Reagent (Qiagen) in human kidney 
embryonic (HEK)-293 GripTite cells kindly 
provided by Dr. Daniela Rotin (Toronto, Ontario, 
Canada). Transfected cells were then temperature 
rescued at 27C for 24 h. 
FLIPR membrane potential assay - The 
following steps of the FLIPR assay were 
conducted at 27C. Cells were loaded with 0.5 
mg/ml FLIPR membrane potential dye (Molecular 
Devices, Sunnyvale, CA) in sodium gluconate 
buffer (140 mM sodium gluconate, 0.5 mM 
potassium gluconate, 2 mM calcium gluconate, 2 
mM magnesium gluconate, 10 mM HEPES, 12 
mM sodium bicarbonate, pH 7.4) for 45 min. 
Fluorescence was recorded at excitation of 530 nm 
and emission of 560 nm on the fluorescence plate 
reader (SpectraMax i3X, Molecular Devices). 
Baseline fluorescence was read for 5 min and 
stimulation of CFTR activity by 10 M forskolin 
(Sigma) was read for up to 15 min. The maximum 
peak of activation and the maximum rate during 
the first 5 min of forskolin stimulation, which was 
determined by linear regression with GraphPad 
Prism, were analyzed.  
Cysteine cross-linking – Cells transfected 
with cys-less Wt-CFTR constructs were pre-
treated with the cAMP agonists, 10 M forskolin 
and 100 M 3-Isobutyl-1-methylxanthine (Sigma), 
or vehicle (DMSO) for 30 min at 27C. 50 M 
bismaleimidoethane (BMOE) (Life Technologies, 
Rockford, IL) in Dulbecco’s modified Eagle’s 
medium media (Wisent, St-Bruno, Quebec, 
Canada) was added to HEK-293 GripTite cells 
transfected with the cys-less Wt constructs for 1 h 
on ice as previously described (10). Transfected 
HEK-293 GripTite cells were lysed with 
radioimmunoprecipitation assay buffer (50 mM 
Tris-Base, 150 mM sodium chloride, 1 mM 
EDTA, 1% (v/v) Triton X-100, 0.1% (v/v) SDS, 
1X protease inhibitor cocktail (AMRESCO, 
Cleveland, OH), pH 7.4). Protein samples were 
run on 6% Tris-Glycine sodium dodecyl sulfate 
gels (Life Technologies, Carlsbad, CA) and 
transferred onto nitrocellulose paper. Immunoblots 
were probed for total CFTR protein with human 
CFTR NBD2 specific (amino acid 1204-1211) 
IgG2b mAb596 antibody (1:1000, University of 
North Carolina at Chapel Hill, Chapel Hill, NC, 
code: A4) overnight at 4C and horseradish 
peroxidase-conjugated goat anti-mouse IgG 
secondary antibody (1:2000, Pierce, Rockford, IL) 
for 1 h at room temperature. Immunoblots were 
probed for phosphorylated CFTR protein with 
phosphorylation-sensitive (anti-Ser813, quenched 
by PKA phosphorylation) IgG1 mAb217 antibody 
(1:1000, University of North Carolina at Chapel 
Hill, code: A3) overnight at 4C and horseradish 
peroxidase-conjugated goat anti-mouse IgG 
secondary antibody (1:2000, Pierce) for 1 h at 
room temperature. The specificities of these 
primary antibodies on CFTR epitopes were 
previously described (8,50,51). Protein loading 
was normalized with the calnexin-specific rabbit 
pAb (1:10000, Sigma, cat. no.: C4731) primary 
antibody overnight at 4C and horseradish 
peroxidase–conjugated goat anti-rabbit IgG 
secondary antibody (1:10000, Pierce) for 1 h at 
room temperature. Blots were exposed with 
Amersham enhanced chemiluminescent reagent 
(GE Healthcare Life Sciences, Mississauga, 
Ontario, Canada) on the Li-Cor Odyssey Fc (LI-
COR Biosciences, Lincoln, NE) in a linear range 
of exposure. Normalized densitometry of 
immunoblot bands to total protein signal were 
analyzed with ImageJ 1.48v (52). 
Expression and function of disease-
causing loop mutants – Immunoblotting of 
disease-causing loop mutants were performed as 
previously mentioned with the exception that the 
immunoblots were probed with human CFTR 
NBD2 IgG2b mAb596 antibody (1:2000, 
University of North Carolina, code: A4) overnight 
at 4C and horseradish peroxidase-conjugated goat 
anti-mouse IgG secondary antibody (1:4000, 
Pierce) for 1 h at room temperature. The EC50 
values of phosphorylation-dependent channel 
activation of Wt, R170G and A1067T were 
determined by activating the channel with various 
forskolin concentrations (i.e. 0, 0.08, 0.16, 0.31, 
0.63, 1.25, 2.5, 5 and 10 M) and normalizing the 
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maximum peak of activation to no forskolin 
control in the FLIPR membrane potential assay. 
Curves were fit with the dose-response–
stimulation log (agonist) versus response (three 
parameters) fit in GraphPad Prism. Slopes of 
activation within 4.5 min after 0.6 M forskolin 
(the forskolin concentration closest to all the EC50 
values of Wt and the disease-causing ICL mutants) 
were determined by linear regression on GraphPad 
Prism. 
Bioinformatics - The locations of CH 
residues, R170 and A1067, were identified from 
the Dalton-Kalid homology model (17) using the 
molecular graphics package, PyMOL (53). The 
secondary structure predictions of Wt-CFTR and 
the mutants (R170G, A1067T and 
R170G+A1067T) were conducted using the I-
TASSER server (30-33). The ResQ algorithm of I-
TASSER generated the B-factor values by taking 
into account the changes in local structural 
assembly along with the sequence and structural 
profiles (30-33). These values were then 
normalized based on the z-scores (30-33).
 
Addendum: A full-length structural model of the zebrafish CFTR was recently defined by cryo- 
microscopy (54). The model represents the closed state of the channel as it is dephosphorylated and ATP 
free. The R domain in this model lacked stable secondary structure but interestingly, it did confer an 
amorphous density that extended from the inner vestibule of the channel pore all the way down the long 
axis conferred by ICL1, ICL4 and the ATP binding surface of NBD1. Hence, the zebrafish CFTR 
structure is compatible with the idea that phosphorylation of the R domain is poised to indirectly modify 
the transmission interface between the CHs of ICL1, ICL4 and NBD1.     
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FOOTNOTES 
 
The abbreviations used are:  CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance 
regulator; NBD, nucleotide binding domain; CH, coupling helix; ICL, intracellular loop; R domain, 
regulatory domain; PKA, protein kinase A; ABC, ATP-binding cassette; MSD, membrane spanning 
domain; RI, regulatory insertion; Sf9, Spodoptera frugiperda; Ni-NTA, nickel-nitrilotriacetic acid; DDM, 
n-Dodecyl β-D-maltoside; SRCD, synchrotron radiation circular dichroism; λmax, emission wavelength 
maximum; NATA, N-Acetyl-Ltryptophanamide; Cm, midpoint urea concentration; m value, rate of free 
energy change with urea concentration; Ksv, Stern-Volmer constant; cys-less, cysteine-less; BMOE, 
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bismaleimidoethane; FLIPR, fluorescence imaging plate reader; Fsk, forskolin; IBMX, 3-isobutyl-1-
methylxanthine; I-TASSER, Iterative Threading ASSEmbly Refinement; PDB, protein data bank; B-
factor, temperature factor; F508del, deletion of phenylalanine at position 508 
 
 
TABLES 
 
TABLE 1. Stern-Volmer constants of tryptophan fluorescence quenching studies of NATA, non-
PKA and PKA phosphorylated Wt-CFTR. Summary of the Stern-Volmer constants (Ksv) values of 
NATA, non-PKA phosphorylated and PKA phosphorylated Wt-CFTR with the quenchers: acrylamide, 
iodide and cesium. The Ksv values of all quenchers were significantly higher in the NATA sample 
compared to purified full-length Wt-CFTR. The Ksv values of non-PKA phosphorylated and PKA 
phosphorylated Wt-CFTR with acrylamide were not different outside the range of error whereas the Ksv 
values with iodide and cesium were different outside the range of error. Based on these results, we 
propose that intrinsic tryptophan fluorescence may be reporting the tryptophans at the ICL:NBD interface. 
 
 Ksv  (M
-1
) 
Sample Acrylamide Iodide Cesium 
NATA 23.57 ± 2.66 15.81 ± 0.54 3.58 ± 0.10 
Non-PKA phosphorylated CFTR 3.49 ± 0.41 2.85  ± 0.22 0.73 ± 0.22 
PKA phosphorylated CFTR 3.53  ± 0.22 1.89  ± 0.34 1.18 ± 0.38 
 
 
FIGURE LEGENDS 
 
FIGURE 1. PKA phosphorylation modifies the secondary structure of purified full-length Wt-
CFTR. (A) Silver stain gel shows the purity of the full-length Wt-CFTR and that it runs at its expected 
molecular weight of around 140-150 kDa in its core-glycosylated state (band B), the only form of CFTR 
that is expressed in the Sf9 expression system. (B) The scaled delta epsilon () SRCD spectra show that 
purified full-length Wt-CFTR is mostly alpha-helical with characteristic negative peaks at 209 and 222 
nm and a positive peak at 192 nm. SRCD spectra for untreated purified full-length Wt-CFTR in DDM 
micelles (hashed line) and PKA phosphorylated CFTR (solid line). Error bars indicate +/- 1 SD between a 
total of 6 spectra from 3 replicate scans of two aliquots of sample from the same purification. Inset shows 
that phosphorylation significantly increases the peak at 192 nm (****p < 0.0001, t-test) relative to that at 
222 nm.  
 
FIGURE 2. PKA phosphorylation is proposed to modify the transmission interface, as determined 
by intrinsic tryptophan fluorescence studies. (A) Top: linear arrangement of CFTR domains from N-
terminal (Nt) to C-terminal (Ct) end which shows the membrane spanning domain 1 (MSD1) in blue, 
nucleotide binding domain 1 (NBD1) in teal, regulatory (R) domain in green, MSD2 in yellow and NBD2 
in orange. Bottom: The tryptophan residues on a CFTR homology model based on a bacterial transporter, 
Sav1866 (17), are shown as pink sticks and are mostly located at the membrane:solvent interface (with 
the membrane indicated by a rectangle) and intracellular loop (ICL):NBD interface, i.e. the transmission 
interface (indicated by a distinct rectangle below the membrane). The R domain is omitted from this 
homology model of CFTR. (B) Close-up view of the transmission interface with NBD1 of the CFTR 
homology model (17) as this interface has been studied extensively with regard to its role in channel 
activation. This shows that the transmission interface contains the coupling helices (CHs) of the ICLs and 
 at B
IR
K
B
ECK
 CO
LLEG
E on M
arch 10, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Spectroscopic studies of the full-length CFTR 
 15 
NBD1 with multiple tryptophans (i.e. 401, 496 and 1063) shown as pink sticks which are located at the 
interface between NBD1 (teal) and ICL1 (blue) or ICL4 (yellow).  
 
FIGURE 3. PKA phosphorylation modifies the tertiary structure of purified full-length Wt-CFTR, 
possibly within an electrostatic region. (A) Representative intrinsic tryptophan fluorescence readouts of 
PKA phosphorylated full-length Wt-CFTR prior to and after urea denaturation that were normalized to 
fluorescence maxima (Fmax). The intrinsic tryptophan fluorescence of PKA phosphorylated full-length 
Wt-CFTR (solid line) exhibits a red shift in emission wavelength maxima (λmax) upon treatment with the 
final concentration of 8 M urea (dashed line). CFTR was not completely denatured by 8 M urea as the 
trace did not completely overlap with the NATA trace (dotted line) in which all tryptophans are exposed 
to the solvent. Inset: Raw fluorescence intensity of untreated purified full-length Wt-CFTR protein (solid 
line) and treated protein with 8 M urea (dashed line) shows that urea shifts the λmax and decreases the 
fluorescence intensity of purified CFTR. (B) Comparing the red shift in λmax across urea concentrations of 
PKA phosphorylated (open circles) and non-PKA phosphorylated (closed circles) full-length CFTR 
shows that the PKA phosphorylated Wt-CFTR is less susceptible to urea denaturation compared to non-
PKA phosphorylated CFTR. These two denaturation curves are significantly different: non-PKA 
phosphorylated Wt-CFTR has a midpoint urea concentration (Cm) of 2.8 M urea whereas PKA 
phosphorylated Wt-CFTR has a Cm of 4.0 M urea. The “m” value or slope of unfolding was also lower in 
the PKA phosphorylated sample in which the “m” value was 0.8 kcal/molM-1 in the non-PKA 
phosphorylated Wt-CFTR compared to 0.6 kcal/molM-1 in the PKA phosphorylated Wt-CFTR. Error 
bars indicate +/- 1 SD between replicate samples (n = 5 biological replicates and n = 5 technical 
replicates, p = 0.0057, Two-way ANOVA). (C-E) Stern-Volmer plots of tryptophan quenching of purified 
full-length non-PKA phosphorylated (closed circles) and PKA phosphorylated (open circles) Wt-CFTR at 
the major intrinsic tryptophan fluorescence peak, obtained from excitation at 290 nm and emission at 322 
nm, were generated. Quenching with (C) acrylamide shows no difference upon PKA phosphorylation (n = 
3 biological replicates and n = 3 technical replicates) whereas quenching with (D) negatively charged 
iodide (n = 3 biological replicates and n = 3 technical replicates) and (E) positively charged cesium 
quenchers (n = 3 biological replicates and n = 3 technical replicates) showed an opposite quenching effect 
upon PKA phosphorylation, suggesting that phosphorylation modifies an electrostatic environment of the 
protein. Error bars indicate +/- 1 SD between replicate samples. 
 
FIGURE 4. Cys-less CFTR mutants are functionally competent and introduction of V510C/A1067C 
at the ICL4:NBD1 interface affects phosphorylation-dependent channel activity. (A) Left: A cartoon 
showing the location of the residues predicted to interact at the ICL:NBD1 interfaces: V510 on NBD1 and 
A1067 on CH4 at the ICL4:NBD1 interface and R170 on CH1 and W401/E476 on NBD1 at the 
ICL1:NBD1 interface. Cysteine pairs were generated at those residues to investigate interactions at those 
interfaces with cysteine cross-linking studies. Right: Immunoblot shows that the cys-less Wt-CFTR 
mutants were expressed at the endoplasmic reticulum as core-glycosylated protein (represented by band 
B) and at the cell surface as complex-glycosylated protein (represented by band C). (B) Left: Cartoon of 
the basis of the FLIPR response of transiently transfected HEK-293 GripTite cells in sodium (Na-) 
gluconate buffer. Activation of CFTR channel by forskolin leads to membrane depolarization of the cells 
which corresponds to a significant increase in fluorescence intensity compared to vehicle. Right: CFTR 
mutants were stimulated with the cAMP agonist, forskolin (Fsk, 10μM), after 5 min of baseline reading. 
Cys-less Wt along with V510C/A1067C, R170C/W401C and R170C/E476C cys-less Wt-CFTR channels 
were found to retain partial channel activity after forskolin stimulation in the FLIPR assay. The empty 
vector was transfected in HEK-293 GripTite cells as a negative control. (C) The initial slope within the 
first 3 min of forskolin stimulation was significantly lower in V510C/A1067C whereas R170C/W401C 
and R170C/E476C did not have a significantly different rate compared to cys-less Wt. Error bars indicate 
+/- 1 SD between replicate samples (n = 9 biological replicates and n = 3 technical replicates, p < 0.0001 
between cys-less Wt and V510C/A1067C, One-way ANOVA).  
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FIGURE 5. Cysteine cross-linking was observed at the ICL4:NBD1 but not the ICL1:NBD1 
interface, and this interaction was phosphorylation-independent. (A) Immunoblot of negative controls 
consisting of cys-less Wt-CFTR (cys-less), single cysteine mutants (V510C, A1067C, R170C, W401C, 
E476C) and co-transfected single cysteine mutants on different plasmids (V510C+A1067C, 
R170C+W401C, R170C+E476C) were treated with (+) and without (-) BMOE for 1 h at 27C. No 
additional bands except for bands representing the core-glycosylated protein (band B) and complex-
glycosylated protein (band C) were found from the negative controls. (B) Immunoblot shows that a higher 
molecular weight band above 250 kDa which corresponds to the cross-linked product of band C of the 
protein (band X) was only present upon treatment with BMOE on the construct expressing V510C and 
A1067C within the same CFTR protein (V510C/A1067C). This band was not present in the ICL1:NBD1 
cysteine pairs, R170C/W401C and R170C/E476C. This suggests the BMOE was able to capture the 
interaction of the cysteine pairs at the ICL4:NBD1 interface but not at the ICL1:NBD1 interface. (C) 
Immunoblot shows that cross-linked V510C/A1067C was efficiently phosphorylated as shown by a 
decrease in signal following Fsk/IBMX (FI) treatment and detection by a phosphorylation-sensitive 
antibody, 217 (anti-Ser813 of human CFTR), compared to the non-phosphorylation sensitive CFTR 
antibody, 596 (epitope on NBD2 of human CFTR) (n = 3 biological replicates and n = 3 technical 
replicates). (D) Densitometry analysis of band X to total CFTR ratio showed no significant difference 
between the cysteine cross-linking of DMSO and FI pre-treatment of V510C/A1067C. Error bars indicate 
+/- 1 SD between replicate samples (n = 9 biological replicates and n = 3 technical replicates, p = 0.7538, 
Paired t-test).  
 
FIGURE 6. PKA-dependent channel activation and flexibility of NBD1 are affected by disease-
causing mutations at CH1 and CH4. (A) Representative FLIPR traces of Wt-CFTR (Wt) and disease-
causing ICL mutants, R170G on CH1 and A1067T on CH4, stimulated with 0.6 μM forskolin (Fsk) were 
normalized to unstimulated (Wt – no Fsk) traces. Inset: Immunoblot shows that the abundance of 
complex-glycosylated protein (band C) compared to core-glycosylated protein (band B) of the disease-
causing loop mutants was significantly lower than Wt-CFTR. (B) The maximum peak at each forskolin 
concentration was normalized to the unstimulated trace and highest forskolin stimulation (10 μM) to 
generate the forskolin dose-response curves. The EC50 values were quite similar: 0.40 μM for Wt, 0.73 
μM for R170G and 0.54 μM for A1067T. Error bars indicate +/- 1 SD between replicate samples (n = 12 
biological replicates and n = 4 technical replicates). (C) From these calculated EC50 values, the closest 
forskolin concentration from our assay to these EC50 values was 0.6 μM. The initial slopes of activation 
within 4.5 min of forskolin stimulation with 0.6 μM forskolin were then compared. At 0.6 μM, the slopes 
of activation of the disease-causing ICL mutants were significantly lower than Wt: the slope of activation 
for Wt was 0.048 ± 0.002 whereas the slope of activation for R170G was 0.007 ± 0.001 and for A1067T 
was 0.009 ± 0.001. Error bars indicate +/- 1 SD between replicate samples (n = 12 biological replicates 
and n = 4 technical replicates). (D) Normalized temperature factor (B-factor) values, which represent 
protein flexibility, of the residues of R170G (circles) and A1067T (triangles) and both mutations, 
R170G+A1067T (squares) were determined by the protein structure prediction server, I-TASSER (30-
33), and subtracted from Wt. Interestingly, the disease-causing mutations (arrows showing residue 
numbers of the mutations) did not affect the B-factor of the CHs but significantly increased the B-factor 
at the amino-terminal region of the regulatory insertion (residues 405-407) of NBD1. 
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